Rufinamide

Rufinamide (ru-FIN-uh-mide) is the generic name (non-brand name) of a seizure medicine.

In the United States, the Food and Drug Administration (FDA) approved rufinamide in 2008 to be used as an add-on (adjunctive) seizure medicine in children 4 years and older and adults with the Lennox-Gastaut (LGS) syndrome In European countries, rufinamide is marketed under the brand name Inovelon.

Banzel
Tablet
Banzel_200mg.jpg

200-mg Salmon colored tablet imprinted with ""E 262"" on one side

Banzel_400mg.jpg

400-mg Salmon colored tablet imprinted with ""E 263"" on one side

Inovelon
Tablet

100, 200, and 400-milligrams (mg)

Indications

In the United States, the Food and Drug Administration (FDA) approved rufinamide in 2008 to be used as an add-on (adjunctive) seizure medicine in children 4 years and older and adults with the Lennox-Gastaut (LGS) syndrome.

Forms

Banzel is marketed in the United States by Eisai, Inc. The name or appearance may differ in other places. The dose (measured in milligrams, abbreviated ""mg"") will usually be the same. These descriptions apply to the U.S. versions:

Inovelon® is available in European Union countries as tablets in three different strengths: 100, 200, and 400-milligrams (mg). These tablets should be swallowed whole and not chewed.

Dosing

See package insert.

Rufinamide Package insert

In the United States, companies that manufacture medicines are required to publish certain kinds of information about each product. This document is commonly known as a “package insert” because it is usually included with each package of the medicine.

You can also read these documents (also called "prescribing information") online. The U.S. package insert for Banzel (rufinamide) is found at:

Some of the information may differ in other countries.

To learn how to read and understand a package insert, see "How to read a package insert."

Rufinamide References for Professionals

If you visit PubMed, a service of the National Library of Medicine, you can read summaries of studies that have tested rufinamide.

Our Mission

The mission of the Epilepsy Foundation is to lead the fight to overcome the challenges of living with epilepsy and to accelerate therapies to stop seizures, find cures, and save lives.

 
24/7 helpline